Penumbra, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Penumbra reported quarterly adjusted earnings of $1.07 per share, up from 97 cents a year earlier but below the $1.23 analysts expected. Revenue rose 15.6% to $410.15 million, ahead of the $403.35 million analysts expected, and net income was $42.28 million.

Confirmed

Global impact / market context

Profit per sale fell short of analyst expectations even as revenue beat forecasts, which suggests the company earned less on each dollar of sales than Wall Street assumed. That gap can pressure the shares because investors pay for future profit, not just sales growth.

Analyst inference

Analysts had cut their average earnings estimate by about 3% over three months, and the current average rating is hold, meaning most analysts recommend neither buying nor selling. The $374 median price target sits about 14.1% above the last close of $321.34.

Analyst inference

What to watch

1. The average analyst rating is hold: two rate the shares strong buy or buy, eight rate hold, and none rate sell or strong sell. The consensus for the medical equipment peer group is buy. Confirmed
2. Watch whether analysts revise earnings estimates after this report; there were no revisions in the last 30 days, and further cuts could lower the average price target, which is a forecast of where shares may trade. Proposed
3. Watch whether revenue growth of 15.6% carries into future quarters and whether costs that kept earnings below the $1.23 expectation persist, since either outcome could change the hold rating and price target. Analyst inference

Evidence

• Original source link unavailable